Evidence-Based Genetics and Identification of Key Human Alzheimer’s Disease Alleles with Co-morbidities by Le, Duc et al.
Touro Scholar 
Faculty Publications & Research of the TUC 
College of Osteopathic Medicine College of Osteopathic Medicine 
4-10-2020 
Evidence-Based Genetics and Identification of Key Human 
Alzheimer’s Disease Alleles with Co-morbidities 
Duc Le 
Touro University California 
Nicolas Crouch 
Touro University California 
Alyssa Villanueva 
Touro University California 
Phong Ta 
Touro University California 
Roman Dmitriyev 
Touro University California 
See next page for additional authors 
Follow this and additional works at: https://touroscholar.touro.edu/tuccom_pubs 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Le, D., Crouch, N., Villanueva, A., Ta, P., Dmitriyev, R., Tunzi, M., & Murakami, S. (2020). Evidence-Based 
Genetics and Identification of Key Human Alzheimer’s Disease Alleles with Co-morbidities. Journal of 
Neurology and Experimental Neuroscience, 6 (1), 20-24. https://doi.org/10.17756/jnen.2020-069 
Authors 
Duc Le, Nicolas Crouch, Alyssa Villanueva, Phong Ta, Roman Dmitriyev, Matthew Tunzi, and Shin 
Murakami 
This article is available at Touro Scholar: https://touroscholar.touro.edu/tuccom_pubs/139 
Le et al. 20
Evidence-Based Genetics and Identification of Key 
Human Alzheimer’s Disease Alleles with Co-morbidities
Commentary Open Access
https://doi.org/10.17756/jnen.2020-069
Duc Le1, Nicolas Crouch1, Alyssa Villanueva1, Phong Ta1, Roman Dmitriyev1, Matthew Tunzi1 and Shin Murakami2*
1Master of Science in Medical Health Sciences, Department of Basic Sciences, Biotech Academy Internship Program, Touro University California, College of Osteopathic 
Medicine, Vallejo, CA, USA
2Professor,Department of Basic Sciences, College of Osteopathic Medicine, Touro University, California, 1310 Club Drive, Mare Island, Vallejo, 94592, CA, USA
*Correspondence to:
Shin Murakami, PhD, FGSA
Professor, Department of Basic Sciences
College of Osteopathic Medicine
Touro University, California, 1310 Club Drive 
Mare Island, Vallejo, 94592, CA,USA
Tel: +1-707-638-5903
E-mail:  shin.murakami@tu.edu
Received: October 29, 2019
Accepted: April 07, 2020
Published: April 10, 2020
Citation: Le D, Crouch N, Villanueva A, Ta P, 
Dmitriyev R, et al. 2020. Evidence-Based Genetics 
and Identification of Key Human Alzheimer’s 
Disease Alleles with Co-morbidities. J Neurol Exp 
Neurosci 6(1): 20-24.
Copyright: © 2020 Le et al. This is an Open 
Access article distributed under the terms of the 
Creative Commons Attribution 4.0 International 
License (CC-BY) (http://creativecommons.
org/licenses/by/4.0/) which permits commercial 
use, including reproduction, adaptation, and 
distribution of the article provided the original 
author and source are credited.
Published by United Scientific Group
Abstract
Advancements in biomedical research have contributed to increasing the life 
expectancy of humans, but we now observe an increase in age-related diseases 
such as Alzheimer’s disease. Genome-Wide Association Studies (GWAS) and 
linkage studies have identified human genes associated with Alzheimer’s disease 
(referred to as AD genes). A previous study by Vahdati in 2017 has revealed 
the human AD genes and counterparts in model species [1]. Thus, we further 
investigate the co-morbidity genes and alleles. Using ontology analysis combined 
with cluster analysis, the study identified functional pathways enriched among 
the human AD genes, including 179 genes out of 695 human AD genes (26%) 
that were associated with one or more of the four neurological diseases including 
Amyotrophic lateral sclerosis, Multiple sclerosis, Parkinson’s disease, and 
Schizophrenia [1]. More importantly, the results indicate co-morbidities with 
Late-Onset Alzheimer’s Disease (LOAD) and other neurological conditions, 
implying the complexity of the phenotypes in the human AD. The co-morbidity 
genes may account for mixed symptoms for human AD as well as age-related 
risks of infections. Of them, the three genes are well conserved (Angiotensin 
I Converting Enzyme gene, ACE; Methylenetetrahydrofolate Reductase gene, 
MTHFR; and tumor necrosis factor gene, TNF). In this study, we confirmed the 
comorbidity of the three genes associated with AD. We further identified the 
comorbidity of two alleles in the MTHFR gene, C677T and A222V, significantly 
associated with Alzheimer’s disease.  This study provides an example of evidence-
based analysis that is cost-effective and may be an effective approach to develop 
cure-alls for multiple diseases.
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Introduction
Alzheimer’s Disease (AD) has been recognized as a multifactorial disease 
that affects 5.8 million people in America [2]. Despite the controversy, the 
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earliest stage of AD includes an excess production of beta-
amyloid plaques [3]. Genetics is an essential component of the 
onset of AD [4]. AD can be classified as either Early-Onset 
Alzheimer’s Disease (EOAD) or Late-Onset Alzheimer’s 
Disease (LOAD). EOAD symptoms, by definition, are 
manifested before 65 and usually involve the accumulation 
of beta-amyloid plaques. This form is rare and accounts for 
less than 1% of cases, but is usually more aggressive and has 
a shorter survival time. In contrast, most of the AD cases 
fall into the category of LOAD, in which symptoms are 
manifested at the age 65 and older [5]. LOAD shows complex 
genetic patterns, do not follow Mendelian inheritance patterns 
and do not show full penetrance, which likely interacts with 
environmental, lifestyle, and epigenetic factors. The genetic 
factors contribute to the predisposition of the disease with 
multiple genes playing a role. Although the most well-
characterized LOAD gene is the apolipoprotein E (APOE) 
gene, the genome-wide association studies and other linkage 
analysis identified more than 100 genes [1, 6], which remain 
to be investigated.    
Using meta-analysis, the data from Genome-Wide 
Association Studies (GWAS) were compiled to extract and 
identify single nucleotide polymorphisms that are associated 
with Alzheimer’s disease [7-9]. Both the Alzgene database [10] 
and the National Institute of Aging Genetics of Alzheimer’s 
Disease Data storage site (niagads.org) were referenced. This 
study further performed a meta-analysis of the three genes 
that show co-morbidities with other neurological diseases. 
We narrowed down our search by accounting for mechanisms 
and inhibitor drugs. The drugs may have a significant impact 
on the symptoms of AD, which may provide an effective 
intervention for treating the symptoms of AD. We found 
significant correlations to justify further study, including the 
model systems such as the semi-automated system developed 
using the nematode C. elegans [11]. 
Methods
Meta-analysis was performed as described previously [1]. 
To compare the previous data, publications from January 1, 
2013 to April 15, 2017 were investigated from the PubMed 
database and Scopus to evaluate the genes that are associated 
with Alzheimer’s disease. Searches were done for English 
peer-reviewed articles, with their dates and p-values organized 
into an Excel spreadsheet. The p-values were evaluated to 
determine the validity of the studies. The study was determined 
valid if the p-value corresponds to a 95% confidence interval. 
Articles pertaining to the 3 AD genes of interest (ACE, 
MTHFR, and TNF) were searched using Scopus and 
PubMed. General keywords were used first and then more 
keywords were added to help narrow down results. Scopus was 
accessed by going to the website (scopus.com). PubMed was 
accessed by going to the website (ncbi.mln.nih.gov). When 
searching for specific genes, we used the keyword, either TNF, 
MTHFR, or ACE. For articles pertaining to the ACE gene, 
angiotensin-converting enzyme had to be entered fully in the 
box. Entering ACE in the search could yield false positives in 
PubMed, where the database includes articles that involve the 
SpanishFundacióACE foundation which were excluded from 
the analysis. 
Keywords including Alzheimer’s, GWAS, Aging and 
Dementia, were systematically used to search the literature 
relevant to each gene (ACE, MTHFR and TNF). We tested 
the gene name plus all the combinations of the keywords. The 
keywords used were indicated in results section. Typically, three 
keywords (Alzheimer’s, GWAS and each gene) are sufficient 
to narrow down the literature that was below a total of 10 or 
less for each gene.  PubMed and Scopus yielded the highest 
number of articles that demonstrated significant associations 
with ACE and AD. Further searches were done primarily to 
focus on the mechanisms of ACE inhibiting drugs. The drug 
names were identified by using the keyword, ACE inhibitor 
using PubMed, Scopus and UpToDate (UpToDate.com). 
Results
We conducted a systematic review using PubMed and 
Scopus between 2013 and 2017 (methods). The result was 
summarized in table 1 and figure 1. The two searches provided 
a total of 751 publications (Table 1). The analysis was done 
through a current literature search on GWAS involving 
ACE, TNF, and MTHFR. This included the review of 751 
publications total. Of the 751 publications, 569 articles were 
from PubMed and 182 articles were from Scopus.  
Importantly, ACE, TNF, and MTHFR were found to be 
risk factor genes in other neurological disorders, including 
ALS (Amyotrophic Lateral Sclerosis), MS (Multiple 
Sclerosis), PD (Parkinson’s Disease), and Schizophrenia [1]. 
Figure 1: The breakdown of literatures and the gene of focus on the 
PubMed and Scopus databases.
Table 1: A summary of the search results from PubMed and Scopus.
Initial search: 751 publications total
PubMed: 569 publications
(keywords; No of literatures) 
Scopus: 182 publications
(keywords; No of literatures)
ACE + GWAS 102 ACE + GWAS 41
TNF + GWAS 337 TNF + GWAS 98
MTHFR + GWAS 130 MTHFR + GWAS 43
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Table 2 confirms that our previous study is the first report of 
the three AD genes associated with Alzheimer’s disease (Table 
2). We further searched for the alleles of the ACE, TNF, and 
MTHFR genes that are associated with Alzheimer’s disease.
MTHFR
The search on PubMed for GWAS studies on MTHFR 
provided a total of 130 publications. Narrowing down the 
search by adding Alzheimer’s to the key terms filtered 
this total down to a total of 8 publications. Of these 8 
publications, five indicated a significant correlation between 
the MTHFR gene and AD (Table 3 and Figure 1). Further 
analysis ofMTHFRidentified two alleles, C677T and A222V 
with statistical significance (Table 3). Search for MTHFR 
on Scopus led to a total of 43 publications. It is not known 
about the functions of the MTHFR alleles. Searching for 
studies on PD and MTHFR genes returned a total of 50 
publications on PubMed (summarized in Table 4). Limiting 
the same search parameters to only GWAS studies led to a 
total of 5 publications. Of those 5 publications, one study 
demonstrated a significant association with susceptibility to 
PD for individuals in Asian and European populations with 
the functional SNP, rs1801133. A search conducted on studies 
focusing on ALS and MTHFR yielded 9 studies. Of those 9 
studies, 2 were GWAS studies (Table 5).
ACE
The search including both ACE and GWAS yielded 102 
publications. Adding the keyword of Alzheimer’s identified a 
total result of 7 publications focusing on ACE on PubMed 
(Figure 1). Only 4 of these articles demonstrated a significant 
relationship between ACE genes and the cognitive symptoms 
of AD (Supplementary Table 1). The articles provide an 
association between AD and the genes, which do not provide 
information about specific alleles. Thus, no specific allele was 
found. Similarly, of the 182 publications identified by Scopus, 
the additional keyword, ACE, narrowed down the results to 8 
publications (out of 182). Three of these publications showed 
significant p-values, resulting in no alleles in the gene. 
Another search conducted for Parkinson’s and ACE was 
performed on PubMed, leading to a total of 75 publications 
(Table 4). Adding GWAS as a parameter yielded only 1 study 
and no clear alleles. Searches for studies on ACE in the context 
of ALS and dementia resulted in a total of 13 studies, with 
only 1 of those being a GWAS study (Table 5).
TNF
PubMed yielded a total of 337 publications involving 
GWAS studies and TNF genes. A search for TNF genes 
in the background of AD and GWAS resulted in a total 
of 6 publications. Only 3 of the 6 publications indicated a 
significant relationship between the influence of TNF and the 
symptoms of AD (Supplementary Table 2). No alleles were 
found. Similarly, a keyword, TNF, on Scopus yielded a total 
of 98 publications, which do not provide information about 
specific alleles. A search on PubMed for studies involving PD 
and TNF genes yielded 209 publications. Limiting the search 
to GWAS studies involving PD and TNF genes led to a result 
Table 2: Publications involving GWAS studies with a focus on ACE genes 
and AD.
PMID Date of Publication Gene P-value
29777097 5/12/2018 ACE 5 × 10-8
28650998 6/26/2017 ACE 0.358*
28553317 5/12/2017 ACE, TNF, MTHFR 7.73 × 10-13
26159191 9/1/2015 ACE N/A
23857120 6/19/2014 ACE ATP5H/KCTD2 5 × 10-6
22917148 8/23/2012 ACE, APOE, PICALM N/A
20413850 2010 ACE N/A
19501718 2009 ACE, CHRNB2, GAB2 N/A
(*- not significant)
Table 3: Results pertaining to GWAS studies involving the MTHFR 
gene.
PMID Date of Publication Gene P-value
28553317 5/12/2017 MTHFR N/A
27713094 9/18/2016 MTHFR C677T N/A
23916622 8/3/2013 MTHFR C677T 0.004
23754956 6/9/2013 MTHFR A222V 9.5 × 10-53
20413850 4/20/2010 MTHFR N/A
18258338 10/30/2009 MTHFR C677T 0.031
18830724 10/2/2008 MTHFR 0.03
27031476 3/22/2006 MTHFR C677T 2.9 × 10-5
All publications on GWAS studies focusing on MTHFR in context of AD 
are included. Three of these publications did not yield any p-values.
Table 5: Results pertaining to GWAS studies involving ALS and the 
ACE, MTHFR, or TNF genes.
PMID Date of Publication Gene P-value
28553317 5/12/2017 ACE, MTHFR, TNF N/A
27713094 7/1/2017 MTHFR N/A
27487029 8/3/2016 TNF N/A
Table 4: Results pertaining to GWAS studies involving PD and the ACE, 
MTHFR or TNF genes.
PMID Date of Publication Gene P-value
25143327 8/20/2014 ACE N/A
28927418 9/19/2017 MTHFR N/A
24694231 2/1/2014 MTHFR N/A
27713094 7/1/2017 MTHFR N/A
23916622 11/15/2013 MTHFR 0.0149, 0.0178
28553317 5/12/2017 MTHFR, TNF N/A
23380027 9/1/2013 TNF N/A
27487029 8/3/2016 TNF 0.006
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of 4 publications, one study demonstrated a relationship 
between PD and TNF genes with a p-value of 0.006, but 
none of the studies was able to elucidate any specific alleles. 
Searching for studies involving TNF and ALS resulted in 173 
studies, with only 2 of them being GWAS studies (Table 5). 
Drug
A drug search was conducted to determine the most 
affordable drugs in the categories of ACE inhibitors and TNF-
alpha blockers. We did not search for MTHFR as drugs are 
not well known. The search indicated lisinopril to be the most 
cost-effective ACE inhibitor (Table 6). A search on PubMed 
identified 5 publications focused on lisinopril interactions with 
AD. Scopus presented a larger volume of publications directed 
towards both ACE inhibitors and AD. The search on Scopus 
showed 25 studies about lisinopril, but only 3 of them showed 
significant correlations between Lisinopril use and improved 
cognitive function in AD patients. Lastly, another drug search 
identified renflexis, inflectra, and cimzia as three of the most 
cost-effective TNF-alpha blockers (Table 6). 
Discussion
Recent biomedical research has identified a wide variety 
of the genetic and non-genetic interventions that can 
increase the life expectancy of humans. With increasing life 
spans, age-related diseases, including AD have been a major 
concern. Over the past decade, only several genes are known 
to be associated with AD. Three of those AD genes (ACE, 
MTHFR, and TNF) are associated with multiple neurological 
disorders [1], the result of which also suggest three major 
ontology pathways but not limited to, lipoprotein metabolism, 
hemostasis and extracellular organizations. The common 
GWAS hits for AD are also hits in other diseases is evidence 
of complex gene interactions. It insinuates that the three target 
genes may be cure-alls for multiple diseases. In this study, we 
further extended the finding of co-morbidities of the genes 
to commonly seen health problems in the middle age. ACE 
is known to be involved in hypertension and cardiovascular 
disease, which are the leading causes of human mortality [12] 
and the involvement of ACE in AD has been confirmed in other 
studies [13]. ACE is a part of the Renin system that is involved 
in controlling blood pressure and fluid and electrolyte balance 
in the body [14] (Supplementary Figure 1). ACE inhibitors are 
commonly used drugs for the treatment of hypertension, which 
may also be effective for treating AD and other neurological 
disorders. MTHFR codes for the enzyme that is the rate-
limiting step in the methyl cycle that couples with methionine 
and homocysteine metabolism. TNF codes for a cytokine that 
has a role in the activation of acute phase inflammation.  Thus, 
TNF is involved in the response to infection, while ACE is 
involved in the renin system, in which ACE2 is a binding site 
of virus infection, such as a new coronavirus COVID-19 [15, 
16]. The genes are associated with infection, which is a major 
cause of human mortality (e.g., diabetes, hypertension and 
cardiovascular disease) (Coronavirus Disease 2019, cdc.org). 
Lastly, our result showed that the finding is the first evidence 
for all three genes.
The purpose of this study was to analyze the number 
of current studies that have focused on the three AD genes: 
ACE, MTHFR, and TNF. The two databases we used were 
PubMed and Scopus. Our search on PubMed showed a 
relatively even distribution in the number of articles for the 
three AD genes after more parameters were added to filter the 
results. Scopus, on the other hand, showed a more prominent 
number of publications on GWAS studies targeting ACE and 
AD. Despite this, the overall number of publications in our 
literature search shows that the three gene alterations have not 
been studied rigorously concerning AD. This creates room for 
further studies on ACE, MTHFR, and TNF.
The publications for ACE, MTHFR, and TNF showed 
overall similar numbers of significant findings based on 
p-values. However, ACE had a larger number of studies, many 
of which focused on the specific mechanisms of ACE inhibitors. 
Compared to ACE, the other genes do not have widely available 
or cost-effective drugs for further research. TNF blockers, such 
as etanercept and infliximab, can cost several thousand dollars 
[14]. Lisinopril is the most cost-effective drug that has been 
studied in the context of the three genes of interest.  Although 
this may be a valuable aspect to take into consideration, further 
studies including functional analysis of the gene effect on the 
toxicity of beta-amyloid and other AD proteins remains to be 
performed. The recent discovery of muscarinic receptor genes 
as crucial for REM sleep [17] and that on the importance of 
night sleep for removing brain debris [18]. This and earlier 
studies may miss the genes involved in the mechanism of sleep 
and others, while non-coding RNAs [19] are also identified, 
including miR142 [1, 8, 13]. The study of the areas will require 
a further analysis designed to study the mechanisms in the 
future. Computational and artificial intelligence studies will 
open a window to the analysis of the overwhelming amount of 
data that will be beneficial for this type of studies.
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Table 6: A list of drugs identified.
Drug Name* Standard Dose Cost
Prinivil (lisinopril/
ACE inhibitor
5-10 mg once daily
20-40 mg for maintenance




5-10 mg once daily
20-40 mg for maintenance




3-5 mg per kg (of patient 
weight) every 8 weeks




3-5 mg per kg (of patient 
weight) every 8 weeks
$2,817 for 4 vials 
of 100 mg
Cimzia (TNF 
blocker) 200 mg every 2 weeks $4,289 for 200 mg
*- 5 drugs were identified as the most affordable option for ACE inhibitors 
and TNF-alpha blockers. The standard dose, retrieved from MedScape, is 
included for reference.
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